Racial Differences in Productivity Loss Attributable to Rheumatoid Arthritis Among Patients Taking Disease-Modifying Antirheumatic Drugs (DMARDs)

被引：0
|
作者：
Bozzi, Laura M. [1 ]
Gaitonde, Priyanka [1 ]
Shaya, Fadia [1 ]
Tom, Sarah E. [1 ]
机构：
[1] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2016年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1062
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [1] Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
    Grijalva, Carlos G.
    Chung, Cecilia P.
    Arbogast, Patrick G.
    Stein, Charles M.
    Mitchel, Edward F., Jr.
    Griffin, Marie R.
    [J]. MEDICAL CARE, 2007, 45 (10) : S66 - S76
  • [2] Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella, AC
    O'Dell, JR
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (03) : 185 - 192
  • [3] Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients
    Chu, Li-Hao
    Portugal, Cecilia
    Kawatkar, Aniket A.
    Stohl, William
    Nichol, Michael B.
    [J]. ARTHRITIS CARE & RESEARCH, 2013, 65 (02) : 299 - 303
  • [4] Utilization of disease modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA).
    MacLean, CH
    Park, GS
    Traina, SB
    Liu, HH
    Hahn, BH
    Paulus, HE
    Kahn, KI
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S143 - S143
  • [5] The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients
    Khoshroo, Ahmadreza
    Ramezani, Keyvan
    Moghimi, Niusha
    Bonakdar, Moein
    Ramezani, Nazanin
    [J]. INFLAMMOPHARMACOLOGY, 2023, 31 (02) : 689 - 697
  • [6] The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients
    Ahmadreza Khoshroo
    Keyvan Ramezani
    Niusha Moghimi
    Moein Bonakdar
    Nazanin Ramezani
    [J]. Inflammopharmacology, 2023, 31 : 689 - 697
  • [7] PARTICULARITIES OF TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Schiotis, Ruxandra Elena
    Gosa, Dana
    Bocsan, Corina
    Suciu, Soimita
    Buzoianu, Anca Dana
    [J]. FARMACIA, 2017, 65 (03) : 479 - 484
  • [8] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING RITUXIMAB AND CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 882 - 882
  • [9] THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS
    Van Doornum, S.
    Roberts, L.
    Reed, M. D.
    Liew, D.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [10] THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS
    Van Doornum, S.
    Franklyn, K.
    Tacey, M.
    Roberts, C.
    Liew, D.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 : 2 - 2
12345